Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
BRAF V600E PTEN loss TP53 wild-type
|
colorectal cancer
|
sensitive |
MLN0128 + PD-0325901
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).
|
26272063
|